Y-mAb raises $50M round

Immunotherapy play Y-mAbs Therapeutics Inc. (New York, N.Y.) raised $50 million on Oct. 24 in a venture round led by new investor HBM Healthcare Investments. Existing investors also participated.

Y-mAbs' lead candidates are naxitamab (Hu3F8), which is a humanized antibody against ganglioside GD2 (GD2); and burtomab (8H9), a humanized mAb targeting B7-H3 (CD276)...